Difficult-to-Treat Immune-Mediated Inflammatory Diseases Demand Holistic Strategy Beyond Drug Switching

Three decades into rheumatology's "biologic era," a growing subset of patients with immune-mediated inflammatory diseases (搜索)搜索该疾病 continues to fall short of treatment targets — not because the drugs fail, but because the drivers of their suffering extend far beyond inflammation. Two recent viewpoint articles from an international team of researchers are now reshaping how the field defines and manages these "difficult-to-treat" patients.

In a paper published in March in Nature Reviews Rheumatology, Gyorgy Sandor Nagy, MD, of Semmelweis University查看公司主页 in Budapest, Iain B. McInnes, PhD, of the University of Glasgow查看公司主页, and Lilla Gunkl-Tóth, MD, of the University of Pécs and Semmelweis University, argued that difficult-to-treat rheumatoid arthritis (搜索)搜索该疾病 (RA) should not be understood simply as drug-resistant disease.

"One of the main messages of our paper is that difficult-to-treat RA should not be understood simply as drug-resistant RA," Nagy told Healio. "In some patients, persistent inflammation is indeed the dominant problem, but in many others the difficult-to-treat state reflects a combination of biological, pain-related, psychological, comorbidity-related and health-system factors."

A broader discussion published in April 2025 in Lancet Rheumatology, co-authored with András M. Dorgó, MD, also of Semmelweis University查看公司主页, extended these principles across immune-mediated inflammatory diseases (搜索)搜索该疾病. The authors contended that a subset of patients fails to meet treatment goals due to factors ranging from misdiagnosis to demographic and psychosocial reasons.

"Importantly, these factors can overlap further, reinforcing each other," Gunkl-Tóth said. "So, the same clinical endpoint, such as persistent symptoms or failure to reach treatment targets, may arise from very different mechanisms in different patients."

The Psychosocial Dimension: A 'Circulus Vitiosus'

Psychosocial distress — including depression, anxiety, stress, maladaptive coping, and social isolation — can profoundly influence the course of RA, according to Gunkl-Tóth.

"Psychological factors have the ability to amplify pain perception and worsen fatigue, which can result in reduced motivation and make adherence to long-term treatment more difficult," she said.

Leonard H. Calabrese, DO, RJ Fasenmyer chair of clinical immunology at Cleveland Clinic查看公司主页 and chief medical editor of Healio Rheumatology, underscored the clinical stakes. "It is critical to understand that depression prevents people from hitting their treatment target. If you have depression before you get started on treatment with RA medications, your likelihood of reaching target is reduced by half."

The relationship between psychological distress and disease outcomes is likely bidirectional, Gunkl-Tóth noted. "Psychological distress can worsen RA outcomes, but repeated treatment failure, chronic pain, and loss of function can also lead to psychological distress, resulting in a circulus vitiosus that is very hard to break."

Comorbidities and Pain: Confounding the Clinical Picture

Comorbidities represent another major driver of difficult-to-treat status. Nagy highlighted that conditions such as obesity, cardiovascular disease, lung disease, chronic infections, malignancy, metabolic disease, osteoarthritis, and osteoporosis "can all worsen symptoms, impair function, and reduce quality of life" while also complicating the interpretation of disease activity.

Pain, arguably the most common complaint among patients with rheumatic diseases, can be particularly misleading. "Pain in RA is not always proportional to peripheral joint inflammation," Gunkl-Tóth said. "Some patients continue to experience pain even when inflammatory markers improve and synovitis is controlled."

This residual pain may stem from peripheral or central sensitization, nociplastic pain mechanisms, or comorbid fibromyalgia. "If chronic pain mechanisms are not recognized, clinicians may continue to escalate immunosuppressive treatment, even though the dominant driver of symptoms is not active synovitis," Nagy warned, noting that this exposes patients to unnecessary risks without meaningfully improving their symptoms.

Beyond the Disease Activity Score

Brian Andonian, MD, MHSc, assistant professor of medicine and rheumatologist at Duke University School of Medicine查看公司主页, praised the viewpoint articles for advancing a more comprehensive approach. "Better understanding of difficult-to-treat rheumatic disease will help the evaluation and management of all patients under rheumatology care," he said. "Disease activity metrics alone fail to evaluate the whole person, including all of the symptoms, psychosocial factors, and lived experiences that can impair quality of life and well-being."

Andonian urged rheumatologists to adopt whole-person care strategies earlier in the disease course. "Given the many potential benefits of approaching difficult-to-treat patients in this way, rheumatology providers should consider utilizing similar whole-person care strategies earlier and prior to when a patient falls into the difficult-to-treat category."

Multidisciplinary Care and Holistic Strategies

Managing these complex patients demands a multidisciplinary framework. Gunkl-Tóth emphasized that rheumatologists should retain a "central role" in confirming diagnosis, assessing inflammatory activity, and deciding on DMARD escalation. But other specialists are essential.

"Primary care physicians can help manage cardiovascular risk, metabolic disease, obesity, diabetes and smoking," Nagy said. "Psychologists or psychiatrists can support patients with depression, anxiety, coping difficulties or trauma-related distress. Pain specialists can help when central sensitization, fibromyalgia or chronic pain mechanisms dominate." Physiotherapists, occupational therapists, nurses, and pharmacists each contribute critical support for function, education, adherence, and monitoring.

Calabrese pointed to emerging resources within professional organizations. "There is a whole wing rising in the American College of Rheumatology查看公司主页 that is helping patients to get into exercise programs and tai chi, to help with diet and mental health. It is time to put the pieces of the puzzle together."

Andonian called on the ACR and EULAR (搜索)搜索该词条 to "advocate for more research funding, implementation and reimbursement for novel therapeutics, as well as lifestyle and integrative medicine" and to "continue to revisit and expand clinical guidelines to include consideration for these therapies and difficult-to-treat and whole-person care models."

Communication as the First Step

Holistic care begins with empathy and communication. "It begins with empathy," Andonian said. "Providers should get to know their patients and try to understand their lived experiences. Also, they should revisit diagnoses and consider whether additional problems are contributing to a patient's health and well-being."

Gunkl-Tóth outlined the key questions clinicians should ask: "Is there ongoing inflammation? Is the diagnosis correct? Are comorbidities contributing? Is pain being amplified by central mechanisms? Are there psychological, lifestyle or socioeconomic barriers? Is the patient able to take the medication as intended?"

Nagy emphasized the importance of reframing the conversation for patients. "Patients with difficult-to-treat disease often feel that they have failed treatment, but the better framing is that standard treatment pathways have not yet addressed the full complexity of their disease."

"The difficult-to-treat concept gives clinicians a new paradigm in management, as well as a framework to look beyond repeated drug switching and to identify the dominant drivers of poor outcome in each individual patient," Nagy concluded. "That is where the greatest opportunity lies: not only to define difficult-to-treat disease, but to help patients step out of that state."